Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.82)
# 1,742
Out of 4,884 analysts
80
Total ratings
45.76%
Success rate
7.38%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Initiates: Hold | $22 | $20.95 | +5.01% | 16 | Feb 11, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $10.99 | +36.49% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $6.30 | +26.98% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $16.95 | +194.99% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $129.11 | +5.34% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $3.26 | +390.80% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $6.44 | +863.48% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.51 | +694.70% | 6 | Dec 12, 2023 | |
| SAGE Sage Therapeutics | Initiates: Hold | $21 | $9.20 | +128.26% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $18.24 | +497.59% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.16 | +589.66% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.77 | +261.01% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $5 | $0.46 | +984.13% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $3.95 | +51.90% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $3.17 | +562.46% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $97.80 | -76.48% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $23.75 | +51.58% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
Feb 11, 2025
Initiates: Hold
Price Target: $22
Current: $20.95
Upside: +5.01%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $10.99
Upside: +36.49%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $6.30
Upside: +26.98%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $16.95
Upside: +194.99%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $129.11
Upside: +5.34%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $3.26
Upside: +390.80%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $6.44
Upside: +863.48%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.51
Upside: +694.70%
Sage Therapeutics
Dec 12, 2023
Initiates: Hold
Price Target: $21
Current: $9.20
Upside: +128.26%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $18.24
Upside: +497.59%
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $1.16
Upside: +589.66%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $2.77
Upside: +261.01%
Nov 11, 2022
Maintains: Buy
Price Target: $7 → $5
Current: $0.46
Upside: +984.13%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $3.95
Upside: +51.90%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $3.17
Upside: +562.46%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $97.80
Upside: -76.48%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $23.75
Upside: +51.58%